Orphalan Partners with MAP International and WDA to Donate Wilson Disease Drug Globally

Orphalan Partners to Donate and Ensure Access to all Communities

Image Credits: Wilson Disease Org

Announcement

Orphalan SA, a pharmaceutical company targeting rare diseases, announced its partnership with MAP International and the Wilson Disease Association (WDA). This alliance will enable access to Cuvrior® (trientine tetrahydrochloride) to patients suffering from Wilson disease in developing countries. Orphalan will donate a supply of Cuvrior® to MAP International. MAP International is a humanitarian health organization that has over 70 years of experience in providing complex medicines to individuals in need.

Wilson Disease

Wilson Disease is a rare genetic disorder that’s caused by extreme accumulation of copper in the body. This condition can turn into neurological and serious liver complications if not treated. Cuvrior®, a survivor, is an oral copper chelator that received FDA approval in 2022 for adults ' maintenance therapy. This medication is intended for dosing twice a day and can be stored at room temperature.

This effective collaboration is an effort to enable accessibility and reach of Cuvrior® to patients suffering from Wilson disease in underdeveloped regions.

What Role will this New Alliance Play in the Healthcare Market?

MAP International, a non-profit humanitarian organization, will accelerate its vast network of health providers and nonprofit partners. This extended engagement will safe and timely availability of Cuvrior® to needy patients. Whereas, the Wilson Disease Association, a global US-based patient advocacy organization, will accommodate requests from patients and doctors and verify eligibility. This alliance helps Orphalan to fulfill its commitment to elevate global health equity and its investment in rare disease communities. Currently, the supplied Cuvrior, a donation to MAP International, is available for shipment globally for patients.

Views and Statements

Head of US Commercial Organization at Orphalan, Dmitry Paramonov, said, “The mission is to ensure equal care to all individuals, despite where they live. Working with MAP International has helped us expand our reach and access to the treatment option.”

President and CEO of MAP International, Chris Palomb, said, “Our organization is proud and excited to partner with Orphalan. Cuvrior® capability to sustain room temperature has eliminated the biggest challenge of traditional therapies, which require cold storage. This is a lifesaving solution mainly for patients with limited resources and in remote areas, worldwide.”

President of the Wilson Disease Association (WDA), Rhonda Rowland, said, “We have been partnered with MAP International for more than 20 years to provide access to required medicines. We are looking forward to continuing and strengthening our professional relationship with Orphalan to help patients facing disruption in treatment.”